Cyfuse Biomedical K.K.(JP:4892)
Â¥514.00-11.00 (-2.10%)
JP:4892
Cyfuse Biomedical K.K. financials statements
Â¥514.00
At close:-11.00 (-2.10%)
Want to see JP:4892 full AI Analyst Report?
Cyfuse Biomedical K.K. (4892) Ratios
0 Followers
Cyfuse Biomedical K.K. Ratios
JP:4892's free cash flow for Q2 2026 was ¥0.00. For the 2026 fiscal year, JP:4892's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.54 | 5.00 | 5.98 | 6.69 | 6.62 |
| Quick Ratio | 4.44 | 4.91 | 5.91 | 6.63 | 6.46 |
| Cash Ratio | 4.30 | 4.71 | 5.81 | 6.50 | 6.25 |
| Solvency Ratio | -0.48 | -0.86 | -0.54 | -0.40 | 0.22 |
| Operating Cash Flow Ratio | -0.62 | -1.17 | -0.84 | -0.59 | 0.42 |
| Short-Term Operating Cash Flow Coverage | -0.80 | -1.45 | -0.99 | -0.74 | 0.80 |
| Net Current Asset Value | ¥ 2.43B | ¥ 2.26B | ¥ 2.98B | ¥ 3.52B | ¥ 1.81B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.31 | 0.24 | 0.22 | 0.19 | 0.22 |
| Debt-to-Equity Ratio | 0.48 | 0.34 | 0.29 | 0.24 | 0.30 |
| Debt-to-Capital Ratio | 0.32 | 0.25 | 0.22 | 0.19 | 0.23 |
| Long-Term Debt-to-Capital Ratio | 0.19 | 0.11 | 0.10 | 0.09 | 0.16 |
| Financial Leverage Ratio | 1.55 | 1.38 | 1.32 | 1.28 | 1.39 |
| Debt Service Coverage Ratio | -1.16 | -1.61 | -0.94 | -0.75 | 0.81 |
| Interest Coverage Ratio | -58.00 | -94.19 | -71.36 | -57.01 | 13.48 |
| Debt to Market Cap | 0.25 | 0.23 | 0.15 | 0.26 | 0.62 |
| Interest Debt Per Share | 150.68 | 107.11 | 118.12 | 343.23 | 1147.44 |
| Net Debt to EBITDA | 3.05 | 2.56 | 5.50 | 8.60 | -10.93 |
| Profitability Margins | |||||
| Gross Profit Margin | 33.94% | 2.87% | 61.76% | 64.49% | 80.57% |
| EBIT Margin | -358.52% | -1645.91% | -943.21% | -124.04% | 21.20% |
| EBITDA Margin | -343.16% | -1579.76% | -880.82% | -109.54% | 23.81% |
| Operating Profit Margin | -358.52% | -1645.91% | -1141.24% | -113.52% | 9.96% |
| Pretax Profit Margin | -329.57% | -1597.45% | -959.20% | -126.03% | 20.46% |
| Net Profit Margin | -330.67% | -1602.02% | -964.15% | -126.57% | 20.18% |
| Continuous Operations Profit Margin | -330.67% | -1602.02% | -964.15% | -126.57% | 20.18% |
| Net Income Per EBT | 100.33% | 100.29% | 100.52% | 100.43% | 98.61% |
| EBT Per EBIT | 91.92% | 97.06% | 84.05% | 111.02% | 205.35% |
| Return on Assets (ROA) | -17.91% | -24.79% | -13.98% | -9.84% | 5.40% |
| Return on Equity (ROE) | -27.70% | -34.31% | -18.39% | -12.57% | 7.52% |
| Return on Capital Employed (ROCE) | -24.36% | -31.23% | -19.65% | -10.29% | 3.12% |
| Return on Invested Capital (ROIC) | -20.35% | -26.39% | -16.94% | -9.19% | 2.82% |
| Return on Tangible Assets | -17.92% | -24.82% | -13.99% | -9.85% | 5.41% |
| Earnings Yield | -14.71% | -23.97% | -9.90% | -13.66% | 15.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.07 | 0.85 | 1.23 | 5.36 | 12.27 |
| Payables Turnover | 2.20 | 3.40 | 18.27 | 41.60 | 16.63 |
| Inventory Turnover | 1.72 | 0.95 | 0.51 | 3.29 | 2.23 |
| Fixed Asset Turnover | 1.49 | 0.38 | 0.36 | 1.53 | 8.55 |
| Asset Turnover | 0.05 | 0.02 | 0.01 | 0.08 | 0.27 |
| Working Capital Turnover Ratio | 0.08 | 0.02 | 0.02 | 0.12 | 0.34 |
| Cash Conversion Cycle | 118.00 | 705.11 | 996.85 | 170.17 | 171.60 |
| Days of Sales Outstanding | 71.95 | 428.96 | 297.62 | 68.06 | 29.75 |
| Days of Inventory Outstanding | 212.25 | 383.65 | 719.21 | 110.88 | 163.79 |
| Days of Payables Outstanding | 166.20 | 107.50 | 19.98 | 8.77 | 21.94 |
| Operating Cycle | 284.20 | 812.61 | 1016.82 | 178.94 | 193.54 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -60.76 | -94.47 | -71.98 | -151.29 | 322.75 |
| Free Cash Flow Per Share | -66.11 | -95.42 | -74.47 | -236.87 | 322.75 |
| Dividend Paid and CapEx Coverage Ratio | -11.35 | -99.92 | -28.87 | -1.77 | 0.00 |
| Capital Expenditure Coverage Ratio | -11.35 | -99.92 | -28.87 | -1.77 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.41 | -0.89 | -0.62 | -0.44 | 0.28 |
| Operating Cash Flow to Sales Ratio | -2.32 | -13.97 | -9.20 | -1.08 | 0.23 |
| Free Cash Flow Yield | -11.21% | -21.11% | -9.77% | -18.21% | 17.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.80 | -4.17 | -10.10 | -7.32 | 6.35 |
| Price-to-Sales (P/S) Ratio | 22.48 | 66.83 | 97.41 | 9.27 | 1.28 |
| Price-to-Book (P/B) Ratio | 1.88 | 1.43 | 1.86 | 0.92 | 0.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.92 | -4.74 | -10.23 | -5.49 | 5.62 |
| Price-to-Operating Cash Flow Ratio | -9.71 | -4.78 | -10.59 | -8.60 | 5.62 |
| Price-to-Earnings Growth (PEG) Ratio | 0.34 | -0.10 | 0.18 | 0.05 | -0.01 |
| Enterprise Value Multiple | -3.51 | -1.67 | -5.56 | 0.14 | -5.55 |
| Enterprise Value | 2.78B | 1.44B | 2.99B | -58.60M | -936.07M |
| EV to EBITDA | -3.51 | -1.67 | -5.56 | 0.14 | -5.55 |
| EV to Sales | 12.03 | 26.43 | 48.96 | -0.16 | -1.32 |
| EV to Free Cash Flow | -4.77 | -1.87 | -5.14 | 0.09 | -5.79 |
| EV to Operating Cash Flow | -5.20 | -1.89 | -5.32 | 0.15 | -5.79 |
| Tangible Book Value Per Share | 312.91 | 315.28 | 409.50 | 1411.12 | 3786.83 |
| Shareholders’ Equity Per Share | 313.30 | 315.80 | 410.06 | 1413.17 | 3796.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.01 | -0.00 | 0.01 |
| Revenue Per Share | 26.24 | 6.76 | 7.82 | 140.38 | 1415.07 |
| Net Income Per Share | -86.78 | -108.34 | -75.42 | -177.67 | 285.52 |
| Tax Burden | 1.00 | 1.00 | 1.01 | 1.00 | 0.99 |
| Interest Burden | 0.92 | 0.97 | 1.02 | 1.02 | 0.97 |
| Research & Development to Revenue | 0.00 | 8.62 | 6.14 | 0.81 | 0.38 |
| SG&A to Revenue | 3.92 | 7.86 | 1.77 | 0.25 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.70 | 0.87 | 0.96 | 0.86 | 1.11 |
Currency in JPY

